Intensity Therapeutics, Inc. SEC filings INTS
Intensity Therapeutics, Inc. has 246 filings in SEC EDGAR's recent list, going back to Jan 18, 2013. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| S-8 | Employee stock plan registration | Jul 8, 2026 | — |
| 424B5 | Prospectus supplement | Mar 23, 2026 | — |
| S-8 | Employee stock plan registration | Jan 23, 2026 | — |
| 424B5 | Prospectus supplement | Dec 4, 2025 | — |
| 424B5 | Prospectus supplement | Nov 3, 2025 | — |
| S-8 | Employee stock plan registration | Jun 27, 2025 | — |
| 424B5 | Prospectus supplement | Jun 18, 2025 | — |
| 424B5 | Prospectus supplement | Jun 12, 2025 | — |
| FWP | Free writing prospectus | Jun 11, 2025 | — |
| 424B5 | Prospectus supplement | Jun 11, 2025 | — |
| 424B5 | Prospectus supplement | Jun 11, 2025 | — |
| 424B4 | Prospectus | Apr 25, 2025 | — |
| S-1/A | Amended registration statement | Apr 24, 2025 | — |
| FWP | Free writing prospectus | Apr 23, 2025 | — |
| S-1 | Registration statement | Apr 22, 2025 | — |
| 424B3 | Prospectus | Dec 20, 2024 | — |
| S-1 | Registration statement | Dec 13, 2024 | — |
| 424B5 | Prospectus supplement | Nov 22, 2024 | — |
| 424B5 | Prospectus supplement | Nov 20, 2024 | — |
| S-8 | Employee stock plan registration | Jul 3, 2024 | — |
| S-3 | Shelf registration | Jul 3, 2024 | — |
| S-3 | Shelf registration | Jul 3, 2024 | — |
| S-8 | Employee stock plan registration | Aug 22, 2023 | — |
| 424B4 | Prospectus | Jun 30, 2023 | — |
| S-1MEF | Registration statement | Jun 29, 2023 | — |
| S-1/A | Amended registration statement | Jun 29, 2023 | — |
| FWP | Free writing prospectus | Jun 23, 2023 | — |
| S-1/A | Amended registration statement | Jun 23, 2023 | — |
| S-1/A | Amended registration statement | Jun 9, 2023 | — |
| FWP | Free writing prospectus | Jun 1, 2023 | — |
| S-1/A | Amended registration statement | May 18, 2023 | — |
| FWP | Free writing prospectus | Feb 13, 2023 | — |
| FWP | Free writing prospectus | Feb 9, 2023 | — |
| S-1/A | Amended registration statement | Jan 27, 2023 | — |
| FWP | Free writing prospectus | Jan 13, 2023 | — |
| S-1/A | Amended registration statement | Jan 13, 2023 | — |
| S-1/A | Amended registration statement | Nov 2, 2022 | — |
| S-1/A | Amended registration statement | Oct 3, 2022 | — |
| FWP | Free writing prospectus | Sep 20, 2022 | — |
| S-1/A | Amended registration statement | Sep 20, 2022 | — |
| S-1/A | Amended registration statement | May 16, 2022 | — |
| FWP | Free writing prospectus | Apr 20, 2022 | — |
| S-1/A | Amended registration statement | Apr 20, 2022 | — |
| FWP | Free writing prospectus | Jan 7, 2022 | — |
| S-1/A | Amended registration statement | Jan 7, 2022 | — |
| FWP | Free writing prospectus | Dec 16, 2021 | — |
| S-1/A | Amended registration statement | Dec 9, 2021 | — |
| S-1/A | Amended registration statement | Dec 8, 2021 | — |
| FWP | Free writing prospectus | Nov 24, 2021 | — |
| S-1/A | Amended registration statement | Nov 18, 2021 | — |
| S-1/A | Amended registration statement | Nov 12, 2021 | — |
| S-1 | Registration statement | Oct 28, 2021 | — |
Showing 52 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- INTS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Shelton, CT
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1567264
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.